{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:06:21Z","timestamp":1777950381431,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115020","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:06:53Z","timestamp":1687327613000},"page":"115020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice"],"prefix":"10.1016","volume":"165","author":[{"given":"M.","family":"Rottura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.A.","family":"Drago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Molonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Scoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gigliotti De Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Arcoraci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Imbalzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115020_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115020_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115020_bib3","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115020_bib4","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2023.115020_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115020_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.biopha.2023.115020_bib7","unstructured":"Agenzia Italiana del Farmaco, Nota 97, (2020). https:\/\/www.aifa.gov.it\/documents\/20142\/1728116\/nota-97.pdf (accessed February 14, 2023)."},{"key":"10.1016\/j.biopha.2023.115020_bib8","unstructured":"European Medicines Agency, Xarelto\u00ae, Summary of Product Characteristics, 2009. (2009). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf (accessed February 14, 2023)."},{"key":"10.1016\/j.biopha.2023.115020_bib9","unstructured":"European Medicines Agency, Lixiana\u00ae, Summary of Product Characteristics, (2015). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_en.pdf (accessed February 14, 2023)."},{"key":"10.1016\/j.biopha.2023.115020_bib10","unstructured":"European Medicines Agency, Eliquis\u00ae, Summary of Product Characteristics, (2011). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf (accessed February 14, 2023)."},{"key":"10.1016\/j.biopha.2023.115020_bib11","unstructured":"European Medicines Agency, Pradaxa\u00ae, Summary of Product Characteristics, (2009). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf (accessed February 14, 2023)."},{"key":"10.1016\/j.biopha.2023.115020_bib12","first-page":"1612","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Eur."},{"key":"10.1016\/j.biopha.2023.115020_bib13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/jcpt.13391","article-title":"Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database","volume":"46","author":"Barbieri","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.115020_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17425255.2020.1700952","article-title":"Clinically relevant drug interactions between newer antidepressants and oral anticoagulants","volume":"16","author":"Spina","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2023.115020_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.biopha.2023.115020_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0895-4356(96)00025-X","article-title":"Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis","volume":"49","author":"Sun","year":"1996","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.biopha.2023.115020_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2012.11.026","article-title":"Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of atrial fibrillation management [ISAF] study","volume":"111","author":"Zoni-Berisso","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2023.115020_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4070\/kcj.2017.0146","article-title":"A prospective survey of atrial fibrillation management for real-world guideline adherence: comparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry","volume":"47","author":"Kim","year":"2017","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.biopha.2023.115020_bib19","first-page":"6","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"EP Eur."},{"key":"10.1016\/j.biopha.2023.115020_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u2018Atrial Fibrillation Better Care\u2019 pathway in patients with atrial fibrillation: impact on clinical outcomes\u2014a systematic review and meta-analysis of 285,000 patients","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.biopha.2023.115020_bib21","unstructured":"R. Nieuwlaat, A. Capucci, G.Y.H. Lip, S.B. Olsson, M.H. Prins, F.H. Nieman, J. L\u00f3pez-Send\u00f3n, P.E. Vardas, E. Aliot, M. Santini, H.J.G.M. Crijns, D. Andresen, A.J. Camm, W. Davies, S. Le\u00b4vy, G. Breithardt, S. Cobbe, J.Y. le Heuzey, M. Manini, C. Bramley, V. Laforest, C. Taylor, S. del Gaiso, K. Huber, G. de Backer, V. Sirakova, R. Cerbak, P. Thayssen, S. Lehto, J.J. Blanc, F. Delahaye, B. Kobulia, U. Zeymer, D. Cokkinos, K. Karlocai, I. Graham, E. Shelley, S. Behar, A. Maggioni, L. Gonc\u00b8alves, V. Grabauskiene, I. Asmussen, J. Deckers, J. Stepinska, V. Mareev, Z. Vasiljevic, I. Riecansky, M.F. Kenda, A. Alonso, A. Rosengren, P. Buser, T. Okay, O. Sychov, K. Fox, P. Schofield, M. Simoons, D. Wood, A. Battler, E. Boersma, K. Fox, M. Komajda, K. McGregor, B. Mulder, S. Priori, L. Ryde\u00b4n, A. Vahanian, W. Wijns, Sanofi-Aventis, S. v Grigoryan, I. Apetyan, S. Aroyan, L. Azarapetyan, A. Anvari, M. Gottsauner-Wolf, S. Pfaffenberger, K. Aydinkoc, K. Kalla, M. Penka, H. Drexel, P. Langer, L.A. Pierard, V. Legrand, D. Blommaert, E. Schroeder, I. Mancini, P. Geelen, P. Brugada, M. de Zutter, C. Vrints, M. Vercammen, M. Morissens, B. Borisov, V.A. Petrov, M. Marinova, A. Assen, R. Goudev, Y. Peychev, V. Stoyanovsky, E. Stoynev, S. Kranjcevic, J. Moutiris, M. Ioannides, D. Evequoz, J. Spacilova, M. Novak, M. Eisenberger, J. Mullerova, J. Kautzner, L. Riedlbauchova, J. Petru`, M. Taborsky, H. Cappelen, Y.A. Sharaf, B.S.S. Ibrahim, K. Tammam, A. Saad, H. Elghawaby, H.Z. Sherif, H. Farouk, A. Mielke, M. Engelen, P. Kirchhof, P. Zimmermann, F.F. Aviles, J. Rubio, F. Malpartida, M. Corona, L.T. Sanchez, J. Miguel, L. Herrera, A. Quesada, A.J.M. Garcia, C.S. Gonzalez, M.S.A. Juango, J. Berjon-Reyero, J.M. Alegret, J.M.C. Fernandez, C. Carrascosa, R.A.F. Romero, M.G. Lara, J.L.L. Sendon, J.J.G. de Diego, L.S. Martin, M. Irurita, N.H. Guttierez, J.R.S. Rubio, I. Antorrena, A.B. Paves, A. Salvador, M.D. Orriach, A.A. Garcia, F. Epelde, V.B. Martinez, A.B. Sanchez, C.P. Galvez, R.F. Rivero, A.H. Madrid, G. Baron-Esquivias, R. Peinado, J.A.G. Guindal, T.R. Vera, E.L. Fernandez, R. Gayan, J. Garcia, A. Bodegas, J.T. Lopez, J.M. Florez, C.L. Cabezas, E.V.R. de Castroviejo, J.M. Bellido, M.E. Ruiz, K. Savolainen, M. Nieminen, L. Toivonen, M. Syvanne, M. Pietila, D. Galley, C. Beltra, A. Gay, J.C. Daubert, G. Lecocq, C. Poulain, J.G.F.C. Cleland, R. Shelton, A. Choudhury, G. Abuladze, I. Jashi, A. Tsiavou, G. Giamouzis, N. Dagres, A. Kostopoulou, D. Tsoutsanis, C. Stefanadis, G. Latsios, I. Vogiatzis, A. Gotsis, P. Bozia, M. Karakiriou, S. Koulouris, J. Parissis, G. Kostakis, N. Kouris, D. Kontogianni, K. Athanasios, A. Douras, T. Tsanakis, M. Marketou, N. Patsourakos, L. Czopf, R. Halmosi, I. Pre\u00b4da, E. Csoti, A. Badics, B. Strasberg, N.A. Freedberg, A. Katz, E. Zalzstein, A. Grosbard, E. Goldhammer, M. Nahir, M. Epstein, I. Vider, D. Luria, L. Mandelzweig, B. Aloisi, A. Cavallaro, E. Antonielli, B. Doronzo, D. Pancaldo, C. Mazzola, L. Buontempi, V. Calvi, G. Giuffrida, A. Figlia, F. Ippolito, G.P. Gelmini, N. Gaibazzi, V. Ziacchi, F. de Tommasi, F. Lombardi, C. Fiorentini, P. Terranova, P. Maiolino, M. Albunni, P. Pinna-Pintor, S. Fumagalli, G. Masotti, L. Boncinelli, D. Rossi, G.M. Santoro, M. Fioranelli, F. Naccarella, S.S. Maranga, G. Lepera, B. Bresciani, E. Seragnoli, M.C. Forti, V. Cortina, G. Baciarello, P. Cicconetti, A. Lax, F. Vitali, D. Igidbashian, L. Scarpino, S. Terrazzino, L. Tavazzi, F. Cantu, F. Pentimalli, S. Novo, G. Coppola, G. Zingarini, G. Ambrozio, P. Moruzzi, S. Callegari, G. Saccomanno, P. Russo, E. Carbonieri, A. Paino, M. Zanetta, E. Barducci, R. Cemin, W. Rauhe, W. Pitscheider, M. Meloni, S.M. Marchi, M. di Gennaro, S. Calcagno, P. Squaratti, F. Quartili, P. Bertocchi, M. de Martini, G. Mantovani, R. Komorovsky, A. Desideri, L. Celegon, L. Tarantini, G. Catania, D. Lucci, F. Bianchini, A. Puodziukynas, A. Kavoliuniene, V. Barauskiene, A. Aidietis, J. Barysiene, V. Vysniauskas, I. Zukauskiene, N. Kazakeviciene, L. Georgievska-Ismail, L. Poposka, E. Vataman, A.A. Grosu, W.S. op Reimer, E. de Swart, M. Lenzen, C. Jansen, R. Brons, H. Tebbe, D.C.A. van Hoogenhuyze, M.J. Veerhoek, M. Kamps, D. Haan, N. van Rijn, A. Bootsma, L. Baur, A. van den, H. Fransen, L. Eurlings, J. Meeder, M.J. de Boer, J. Winter, H. Broers, C. Werter, M. Bijl, S. Versluis, M. Milkowska, B. Wozakowska-Kaplon, M. Janion, L. Lepska, G. Swiatecka, P. Kokowicz, J. Cybulski, A. Gorecki, M. Szulc, J. Rekosz, R. Manczak, A.M. Wnuk-Wojnar, M. Trusz-Gluza, A. Rybicka-Musialik, J. Myszor, M. Szpajer, K. Cymerman, J. Sadowski, M. Sniezek-Maciejewska, M. Ciesla-Dul, I. Gorkiewicz-Kot, T. Grodzicki, K. Rewiuk, L. Kubik, J. Lewit, J.M.F.R. de Sousa, R. Ferreira, A. Freitas, J.C.A. Morais, R. Pires, M.J.V. Gomes, P. Gago, R.A.C. Candeias, L. Nunes, J.V.M. Sa, M. Ventura, M. de Oliveira, L.B. Alves, I. Bostaca, C.T. Olariu, G.A. Dan, A. Dan, C. Podoleanu, A. Frigy, G.I.M. Georgescu, C. Arsenescu, C. Statescu, R. Sascau, D.L. Dimitrascu, R. Rancea, Y. v Shubik, D. Duplyakov, M. Shalak, M. Danielyan, A. Galyavich, V. Zakirova, R. Hatala, G. Kaliska, J. Kmec, I. Zupan, J. Tasie`, D. Vokac, N. Edvardsson, D. Poci, H. Gamra, H. Denguir, A. Sepetoglu, A. Arat-Ozkan, M. Orynchak, E. Paliy, I. Vakalyuk, D. Malidze, R. Prog, M.I. Yabluchansky, N.V. Makienko, T. Potpara, S. Knezevic, M. Randjelovic, Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation, Eur Heart J. 27 (2006). https:\/\/doi.org\/10.1093\/eurheartj\/ehl015."},{"key":"10.1016\/j.biopha.2023.115020_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12875-022-01824-6","article-title":"Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study","volume":"23","author":"Halvorsen","year":"2022","journal-title":"BMC Prim. Care"},{"key":"10.1016\/j.biopha.2023.115020_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s11239-022-02655-z","article-title":"Prescribing of anticoagulation for atrial fibrillation in primary care","volume":"54","author":"Martinez","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.biopha.2023.115020_bib24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.115020_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.115020_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/europace\/eut333","article-title":"Atrial fibrillation patients do not benefit from acetylsalicylic acid","volume":"16","author":"Sjalander","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.biopha.2023.115020_bib27","first-page":"18","article-title":"Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy","volume":"17","author":"Hansen","year":"2015","journal-title":"EP Eur."},{"key":"10.1016\/j.biopha.2023.115020_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/01.CIR.0000120509.64740.DC","article-title":"Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation","volume":"109","author":"Stellbrink","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115020_bib29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/jcm9051346","article-title":"Chronic kidney disease management in general practice: a focus on inappropriate drugs prescriptions","volume":"9","author":"Barbieri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2023.115020_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.749686","article-title":"Management of high cardiovascular risk in diabetic patients: focus on low density lipoprotein cholesterol and appropriate drug use in general practice","volume":"8","author":"Rottura","year":"2021","journal-title":"Front Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2023.115020_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.858385","article-title":"Pharmacological treatment of diabetic and non-diabetic patients with coronary artery disease in the real world of general practice","volume":"13","author":"Rottura","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2023.115020_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115020_bib33","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115020_bib34","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40261-018-0693-6","article-title":"Safety of edoxaban 30 mg in elderly patients with severe renal impairment","volume":"38","author":"Fazio","year":"2018","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.biopha.2023.115020_bib35","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/bloodadvances.2019000972","article-title":"Outcomes associated with apixaban vs warfarin in patients with renal dysfunction","volume":"4","author":"Hanni","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2023.115020_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2023.115020_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00228-021-03212-y","article-title":"contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis","volume":"78","author":"al Rowily","year":"2022","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115020_bib39","first-page":"1919","article-title":"Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment","volume":"20","author":"Heidbuchel","year":"2018","journal-title":"EP Eur."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223008107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223008107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:08:58Z","timestamp":1777878538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223008107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"alternative-id":["S0753332223008107"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115020","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115020"}}